Daratumumab Or Darzalex Market Growth Outlook: Trends, Market Size, and Opportunities Over the Next Decade
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Major Innovations Are Driving the Accelerated Growth of the Daratumumab Or Darzalex Market?
The daratumumab or darzalex market is anticipated to grow due to an increase in the incidents of bone marrow cancer. This type of cancer originates in the bone marrow, causing conditions like multiple myeloma and leukemia due to the irregular production of blood cells, which disrupts the normal function of the body. The growth in cases of bone marrow cancer can be linked to various factors, including an older population, better detection techniques, and elements such as environmental factors, lifestyle decisions, and genetic factors. Darzalex, a treatment for multiple myeloma, works by specifically targeting and eradicating abnormal plasma cells in the bone marrow. The American Cancer Society forecasted in January 2024 that there would be 89,190 lymphoma cases and 35,780 myeloma cases, an increase from the previous instances in 2022. Therefore, the daratumumab or darzalex market is expanding due to the surge in bone marrow cancer cases. The daratumumab or darzalex market’s growth is expected to be further propelled by an increased use of biologics and targeted therapies. These therapies are an advanced medical treatment that employs drugs or other substances to accurately locate and combat certain molecules involved in disease development and survival. With the increasing prevalence of chronic diseases and precision medicine advancements, the implementation of biologics and targeted treatments has increased. Daratumumab is used in targeted therapies for its special effect on CD38, a protein found in high levels on the surface of malignant plasma cells in multiple myeloma. In December 2023, the Advanced Therapy Treatment Centers (ATTC) reported that the annual investment in advanced therapies increased by 31% in 2022, and the UK now encompasses 14% of all global commercial ATMP clinical trials. As a result, the growth of the daratumumab or darzalex market is being facilitated by the escalating use of biologics and targeted therapies.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19896&type=smp
#How Will the CAGR of the Daratumumab Or Darzalex Market Influence Its Overall Growth by 2034?
The Daratumumab or Darzalex market has rapidly expanded, moving from $5,093.04 million in 2024 to $5,618.30 million in 2025 at a CAGR of 10.3%. This growth was due to research diversification, easier biomanufacturing, higher monoclonal antibody use, strategic collaborations, and increased mAb production.
The daratumumab or darzalex market will grow rapidly to $8,189.36 million by 2029, showing a CAGR of 10.0%. Growth is due to clinical evidence strength, early treatment adoption, higher biologic demand, patient awareness, blood cancer rise, and chronic disease prevalence. Trends include tech innovation, product releases, services expansion, mergers, radiation tech progress, and collaborations.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19896
What Are the Most Significant Market Trends Transforming theDaratumumab Or Darzalex Market?
The main trend observed in the daratumumab or darzalex market is the increased focus on early intervention methods within oncology treatments – particularly combinations therapies as a means to boost effectiveness when tackling multiple myeloma and other similar cancers. Combination therapies encompass those treatment strategies which utilize two or more therapeutic, often having different action mechanisms, working synergistically to boost effectiveness, combat resistance and improve patient outcomes, possibly reducing the adverse effects associated with monotherapy. For instance, in July 2024, Johnson & Johnson, a US-based pharmaceutical industry company, successfully got DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) approved by U.S. FDA for both induction and consolidation therapy in patients freshly diagnosed of multiple myeloma (NDMM) who are eligible for standard autologous stem cell transplant (ASCT). The newfound approval paves the way for the addition of quadruplet therapy at initial diagnosis, providing a likely improvement in patient outcomes.
What Are the Top Market Players Propelling the Growth of theDaratumumab Or Darzalex Industry?
Major companies operating in the daratumumab or darzalex market include Genmab A/S, Janssen Biotech Inc.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report
Which Primary Segments of the Daratumumab Or Darzalex Market Are Driving Growth and Industry Transformations?
The daratumumab or darzalexmarket covered in this report is segmented –
1) By Drug Type: 100Mg Injection; 400Mg Injection
2) By Distribution Channel: Pharmacies; Hospital; Other Distribution Channels
3) By Application: Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma; Diffuse Large B Cell Lymphoma; Other Applications
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=19896&type=smp
Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Daratumumab Or Darzalex Market?# Market?
North America was the largest region in the daratumumab or darzalex market in 2024. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Daratumumab Or Darzalex Market 2025, By The Business Research Company:
Antibody Contract Manufacturing Global Market Report 2025
Next-Generation Antibody Therapeutics Global Market Report 2025
Antibody Drug Conjugates Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
